Published in Oncotarget on August 10, 2016
It Is Imperative to Establish a Pellucid Definition of Chimeric RNA and to Clear Up a Lot of Confusion in the Relevant Research. Int J Mol Sci (2017) 0.75
Different cancers, same target? Aging (Albany NY) (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Long noncoding RNAs: functional surprises from the RNA world. Genes Dev (2009) 9.14
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Mitochondrial signaling: the retrograde response. Mol Cell (2004) 4.21
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem (1998) 3.80
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res (2007) 2.57
Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther (2002) 2.52
IAP regulation of metastasis. Cancer Cell (2010) 2.47
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev (2009) 2.37
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22
Survivin and IAP proteins in cell-death mechanisms. Biochem J (2010) 2.18
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res (2011) 2.15
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell (2014) 2.12
Modeling metastasis in vivo. Carcinogenesis (2004) 2.02
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 2.01
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2013) 1.96
The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A (2012) 1.92
Mitochondrial transcription and its regulation in mammalian cells. Trends Biochem Sci (2007) 1.88
Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol (2015) 1.87
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res (2011) 1.84
Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells. J Biol Chem (1999) 1.75
ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov (2013) 1.74
Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell (2007) 1.60
Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein. J Biol Chem (2011) 1.54
Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. J Invest Dermatol (2000) 1.46
Replication slippage of different DNA polymerases is inversely related to their strand displacement efficiency. J Biol Chem (1999) 1.44
Targeting survivin in cancer. Cancer Lett (2012) 1.44
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol (2006) 1.37
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
Mutant p53 mediates survival of breast cancer cells. Br J Cancer (2009) 1.33
Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle (2012) 1.32
Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther (2006) 1.32
Mitochondrial gateways to cancer. Mol Aspects Med (2009) 1.28
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep (2004) 1.28
In vitro replication slippage by DNA polymerases from thermophilic organisms. J Mol Biol (2001) 1.23
Copy-choice recombination mediated by DNA polymerase III holoenzyme from Escherichia coli. Proc Natl Acad Sci U S A (1996) 1.21
The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene (2011) 1.17
Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells. Proc Natl Acad Sci U S A (2009) 1.15
Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol Ther (2003) 1.15
The murine misty mutation: phenotypic effects on melanocytes, platelets and brown fat. Genetics (1998) 1.14
Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ (2010) 1.13
Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.09
Expression of a novel non-coding mitochondrial RNA in human proliferating cells. Nucleic Acids Res (2007) 1.07
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol (2015) 1.04
Targeting metastatic melanoma. Annu Rev Med (2011) 1.00
MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol (2014) 0.99
To fight or die - inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr Opin Cell Biol (2010) 0.99
Expression of mitochondrial non-coding RNAs (ncRNAs) is modulated by high risk human papillomavirus (HPV) oncogenes. J Biol Chem (2012) 0.98
E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res (2013) 0.95
The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta (2015) 0.95
Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther (2005) 0.93
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet (2013) 0.93
MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res (2014) 0.93
The mitochondrial lncRNA ASncmtRNA-2 is induced in aging and replicative senescence in Endothelial Cells. J Mol Cell Cardiol (2015) 0.92
Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential. Cancer Res (2006) 0.92
Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J (2004) 0.91
Nuclear localization of the mitochondrial ncRNAs in normal and cancer cells. Cell Oncol (Dordr) (2011) 0.90
Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. J Biol Chem (2014) 0.88
Stable differences in intrinsic mitochondrial membrane potential of tumor cell subpopulations reflect phenotypic heterogeneity. Int J Cell Biol (2011) 0.85
Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron (2008) 0.84
Possible formation of mitochondrial-RNA containing chimeric or trimeric RNA implies a post-transcriptional and post-splicing mechanism for RNA fusion. PLoS One (2013) 0.80
Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc (2014) 0.79
Ascorbic acid increases the activity and synthesis of tyrosinase in B16F10 cells through activation of p38 mitogen-activated protein kinase. Arch Dermatol Res (2011) 0.77
Association between tumorigenic potential and the fate of cancer cells in a syngeneic melanoma model. PLoS One (2013) 0.77
Hormonal regulation of melanogenesis in mouse melanoma and in human melanocytes. Ann N Y Acad Sci (1993) 0.76